Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi Diagnostics expects Access Chlamydia to achieve 20-25% U.S. share in 2-3 years.

This article was originally published in The Gray Sheet

Executive Summary

SANOFI ACCESS CHLAMYDIA IMMUNOASSAY $7-8 MIL. IN ANNUAL U.S. SALES expected within two to three years, the company projects. The test was commercially introduced to the U.S. on May 22, shortly after it received FDA 510(k) clearance. Sanofi Diagnostics Pasteur expects the Access Chlamydia, which generates revenue for Sanofi of about $3.50 per test, to gain a 20-25% share of the U.S. chlamydia test market within that time frame. The U.S. chlamydia market, currently at $30 mil., is growing at about 10% a year, the company estimates.
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT004230

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel